Perception of patients with Alzheimer's Disease on the therapeutic use of cannabis-based medicines
DOI:
https://doi.org/10.33448/rsd-v14i2.48319Keywords:
Alzheimer's; Cannabidiol; Therapy; Medicines; THC; CBD.Abstract
The use of cannabis as a medicinal treatment dates back to the firsts civilizations that used it in several deseases.. Currently, cannabis is used in the treatment of several neurodegenerative diseases, such as Alzheimer's disease and it´s therapeutic use. To assess if whether patients affected by Alzheimer's disease are able to notice improvements in the symptoms of the disease after starting treatment with cannabis-based medication. This is an observational cross-sectional study carried out with a quantitative approach. The results revealed that 58.8% of the participants were male, and it also covered several age groups, with emphasis on ages between 50 and 85 years. Among the participants, 29.9% were widowed and 58% had been through University Education. Approximately 58.8% of the participants used cannabis-based medication less than a year ago, under medical prescription and in conjunction with other medications. The main benefits reported by participants were improvements in memory and appetite, followed by improvement in concentration and sleep. These results suggest a systemic effect of cannabis-based drugs on the body, with emphasis on improvements in memory and appetite. It is important to highlight that in 76.5% of cases, cannabis therapy was performed in conjunction with conventional treatments. Research on the therapeutic effects of cannabis is at an early stage, but it shows promising results in the treatment of conditions such as Alzheimer's Disease. Cannabis therapy has been shown to be safe and effective, especially when combined with traditional treatments. In addition, it is important to emphasize that the use of these drugs should ideally be prescribed by experienced professionals, taking into account the individual benefits and risks of each patient. The use of cannabidiol as a complementary therapy shows promise, but more accessibility to the cost of drugs and more research is still needed so that more people can effectively benefit from these resources.
References
Amin, M. R., & Ali, D. W. (2019). Pharmacology of medical cannabis. In A. N. Bukiya (Ed.), Recent advances in cannabinoid physiology and pathology (pp. 151–165). Springer International Publishing. https://doi.org/10.1007/978-3-030-17493-9_9
Andrade, B. O. de. (2020). O uso da cannabis no tratamento da doença de Alzheimer. [Dissertação de mestrado, Universidade XYZ].
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants, 9(1), 21. https://doi.org/10.3390/antiox9010021
Ballota, D. (2005). Cannabis, uma substância sob controlo permanente. Revista Toxicodependências, 11(1), 25–30.
Carlini, E. A. (2006). A história da maconha no Brasil. Jornal Brasileiro de Psiquiatria, 55, 314–317. https://doi.org/10.1590/S0047-20852006000400013
Choi, S., Huang, B. C., & Gamaldo, C. E. (2020). Therapeutic uses of cannabis on sleep disorders and related conditions. Journal of Clinical Neurophysiology, 37(1), 58–64. https://doi.org/10.1097/WNP.0000000000000527
Cajal, S. R. (1891). Significación fisiológica de las expansiones protoplasmaticas y nerviosas de las células de la sustancia gris. Revista de Ciencias Médicas, 6, 1–13.
Coles, M., Steiner-Lim, G. Z., & Karl, T. (2022). Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease. Frontiers in Neuroscience, 16, 794343. https://doi.org/10.3389/fnins.2022.794343
Corrêa, L. T., Plata, C. F., Ricci, E. L., Nicoletti, M. A., Caperuto, E. C., Spinosa, H. S., Muñoz, J. W. P., & Fukushima, A. R. (2020). Revisão bibliográfica sistemática – Sistema de endocanabinoides: Tendências de uso na farmacologia. Brazilian Journal of Forensic Sciences, Medical Law and Bioethics, 9(2), 146–167. https://doi.org/10.16922/bjfsmb.9.2.146
Escohotado, A. (2004). Historia general de las drogas (p. 192). Editorial Espasa Calpe.
Grosso, A. F. (2020). Cannabis: From plant condemned by prejudice to one of the greatest therapeutic options of the century. Journal of Human Growth and Development, 30(1), 94–97. https://doi.org/10.7322/jhgd.1893
Guinart, D., et al. (2020). Altered signaling in CB1R-5-HT2AR heteromers in olfactory neuroepithelium cells of schizophrenia patients is modulated by cannabis use. Schizophrenia Bulletin, 46(6), 1547–1557. https://doi.org/10.1093/schbul/sbz131
Hampel, H., et al. (2018). Revesting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. The Journal of Prevention of Alzheimer’s Disease, 1–14. https://doi.org/10.14283/jpad.2018.30
Jesus, A. C. J. (2017). Legalização da maconha para fins medicinais. Revista do Curso de Direito do Centro Universitário Brazcubas, 1(1), 35–42.
Kalant, H. (2016). A critique of cannabis legalization proposals in Canada. International Journal of Drug Policy, 34, 5–10. https://doi.org/10.1016/j.drugpo.2016.01.004
Lowe, H., et al. (2021). The endocannabinoid system: A potential target for the treatment of various diseases. International Journal of Molecular Sciences, 22(18), 9866. https://doi.org/10.3390/ijms22189866
Monacelli, F., et al. (2017). Vitamin C, aging and Alzheimer’s disease. Nutrients, 9(7), 670. https://doi.org/10.3390/nu9070670
OBID (Observatório Brasileiro de Informações sobre Drogas). (2011). Informações sobre drogas. https://www.gov.br/cidadania/pt-br/obid. Acesso em 26 abr. 2022.
Pains, C. (2016, abril 26). Pito do Pango: Na década de 30, maconha era vendida em herbanários do Rio. O Globo. https://acervo.oglobo.globo.com/em-destaque/pito-do-pango-na-decada-de-30-maconha-era-vendida-em-herbanarios-do-rio-13352181. Acesso em 26 abr. 2022.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Editora UAB/NTE/UFSM.
Ruver-Martins, A. C., et al. (2022). Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: A case report. Journal of Medical Case Reports, 16(1), 563. https://doi.org/10.1186/s13256-022-03391-6
Shitsuka, R. et al. (2014). Matemática fundamental para tecnologia. (2ed.). Editora Erica
Viana, M. D. B., et al. (2022). Cannabis sativa and cannabidiol: A therapeutic strategy for the treatment of neurodegenerative diseases? Medical Cannabis and Cannabinoids, 5(1), 207–219. https://doi.org/10.1159/000518309
Witkamp, R. F. (2016). Fatty acids, endocannabinoids, and inflammation. European Journal of Pharmacology, 785, 96–107. https://doi.org/10.1016/j.ejphar.2016.05.001
Zuardi, A. W. (2005). History of cannabis as a medicine: A review. Revista Brasileira de Psiquiatria, 28, 1–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fernanda Silva Coutinho ; João Paulo Félix Ferreira; Eduardo Chaves Ferreira Coelho; Jailson Antônio da Luz Júnior; Ricardo Silva Freire; Pedro Gabriel de Lima Carneiro Borges; Graziela Torres Blanch
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
